Hostname: page-component-77f85d65b8-hzqq2 Total loading time: 0 Render date: 2026-04-17T18:11:35.243Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Chahal et al. “Analysis of Bevacizumab Treatment Practices, Survival and Quality of Life Outcomes in Recurrent Glioblastoma Patients”

Published online by Cambridge University Press:  17 November 2025

Egiroh Omene Open the ORCID record for Egiroh Omene [Opens in a new window]
Egiroh Omene*
Affiliation:
Cross Cancer Institute, Edmonton, Alberta, Canada
*
Corresponding author: Egiroh Omene; Email: egiroh.omene@albertahealthservices.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Kim, MM, Umemura, Y, Leung, D. Bevacizumab and glioblastoma: past, present, and future directions. Cancer J. 2018;24:180–186. doi: 10.1097/PPO.0000000000000326.CrossRefGoogle ScholarPubMed
Taal, W, Oosterkamp, HM, Walenkamp, AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943–953.CrossRefGoogle ScholarPubMed
Wick, W, Gorlia, T, Bendszus, M, et al. Lomustine and bevacizumab in progressive glioblastoma. New Engl J Med. 2017;377:1954–1963.CrossRefGoogle ScholarPubMed
Louis, DN, Perry, A, Wesseling, P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23:1231–1251.CrossRefGoogle ScholarPubMed
Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987–996.CrossRefGoogle ScholarPubMed